Hyperactivation of mTOR critically regulates abnormal osteoclastogenesis in neurofibromatosis type 1

Osteoclasts in neurofibromatosis type 1 display enhanced resorption capacity, aberrant morphology, and resistance to serum deprivation

(2010) Eetu Heervä et al.   BONE

Rapamycin: A bone sparing immunosuppressant?

(2010) David F. Romero et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Bone histomorphometry: Standardization of nomenclature, symbols, and units: Report of the asbmr histomorphometry nomenclature committee

(2010) A. Michael Parfitt et al.   JOURNAL OF BONE AND MINERAL RESEARCH

NVP-BEZ235, a dual pan class I PI3 kinase and mTOR inhibitor, promotes osteogenic differentiation in human mesenchymal stromal cells

(2010) Sally K Martin et al.   JOURNAL OF BONE AND MINERAL RESEARCH

High bone turnover and accumulation of osteoid in patients with neurofibromatosis 1

(2009) S. Seitz et al.   OSTEOPOROSIS INTERNATIONAL

Evidence of Increased Bone Resorption in Neurofibromatosis Type 1 Using Urinary Pyridinium Crosslink Analysis

(2009) David A Stevenson et al.   PEDIATRIC RESEARCH

Rapamycin Promotes the Osteoblastic Differentiation of Human Embryonic Stem Cells by Blocking the mTOR Pathway and Stimulating the BMP/Smad Pathway

(2009) Kyu-Won Lee et al.   STEM CELLS AND DEVELOPMENT

TORC1 Is Essential for NF1-Associated Malignancies

(2008) Cory M. Johannessen et al.   CURRENT BIOLOGY

Bone health and fracture rate in individuals with neurofibromatosis 1 (NF1)

(2008) T Tucker et al.   JOURNAL OF MEDICAL GENETICS

Rapamycin inhibits osteoblast proliferation and differentiation in MC3T3-E1 cells and primary mouse bone marrow stromal cells

(2007) Ujjal K. Singha et al.   JOURNAL OF CELLULAR BIOCHEMISTRY